NO894065L - Aromatiske inhibitorer for stereoid 5-alfa-reduktase. - Google Patents

Aromatiske inhibitorer for stereoid 5-alfa-reduktase.

Info

Publication number
NO894065L
NO894065L NO89894065A NO894065A NO894065L NO 894065 L NO894065 L NO 894065L NO 89894065 A NO89894065 A NO 89894065A NO 894065 A NO894065 A NO 894065A NO 894065 L NO894065 L NO 894065L
Authority
NO
Norway
Prior art keywords
beta
alpha
reductase
stereoid
alfa
Prior art date
Application number
NO89894065A
Other languages
English (en)
Other versions
NO894065D0 (no
NO174964C (no
NO174964B (no
Inventor
Dennis Alan Holt
Mark Alan Levy
Brian Walter Metcalf
Original Assignee
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beckman Corp filed Critical Smithkline Beckman Corp
Publication of NO894065D0 publication Critical patent/NO894065D0/no
Publication of NO894065L publication Critical patent/NO894065L/no
Publication of NO174964B publication Critical patent/NO174964B/no
Publication of NO174964C publication Critical patent/NO174964C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J13/00Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0059Estrane derivatives substituted in position 17 by a keto group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J13/00Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0095Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 carbon in position 21 is part of carboxylic group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO894065A 1988-05-25 1989-10-11 Analogifremgangsmåte for fremstilling av aromatiske inhibitorer for steroid 5- NO174964C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19853488A 1988-05-25 1988-05-25

Publications (4)

Publication Number Publication Date
NO894065D0 NO894065D0 (no) 1989-10-11
NO894065L true NO894065L (no) 1991-04-12
NO174964B NO174964B (no) 1994-05-02
NO174964C NO174964C (no) 1994-08-10

Family

ID=22733779

Family Applications (1)

Application Number Title Priority Date Filing Date
NO894065A NO174964C (no) 1988-05-25 1989-10-11 Analogifremgangsmåte for fremstilling av aromatiske inhibitorer for steroid 5-

Country Status (16)

Country Link
EP (1) EP0343954B1 (no)
JP (1) JP2675418B2 (no)
AT (1) ATE114665T1 (no)
AU (1) AU627466B2 (no)
CA (1) CA1331457C (no)
DE (1) DE68919537T2 (no)
DK (2) DK168295B1 (no)
ES (1) ES2065378T3 (no)
GR (1) GR3015135T3 (no)
HK (1) HK1006461A1 (no)
IE (1) IE68858B1 (no)
IL (1) IL91968A (no)
NO (1) NO174964C (no)
PT (1) PT90656B (no)
WO (1) WO1989011282A1 (no)
ZA (1) ZA893971B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138063A (en) * 1984-02-27 1992-08-11 Merck & Co., Inc. 17β-methoxycarbonyl-4-aza-androsten-1-en-3-ones
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
US5162332A (en) * 1990-06-20 1992-11-10 Merck & Co., Inc. Selected 17 β-polyaroyl-4-aza-5 α-androst-1-en-3-ones as steroidal reductase inhibitors
US5061802A (en) * 1990-06-20 1991-10-29 Merck & Co. Inc. 17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents
US5098908A (en) * 1990-06-20 1992-03-24 Merck & Co., Inc. 17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
US5151430A (en) * 1990-06-20 1992-09-29 Merck & Co., Inc. Specific 17β-thiobenzoyl-4-aza-5α-androst-1-en-3-ones as antiandrogen agents
US5091380A (en) * 1990-06-28 1992-02-25 Merck & Co., Inc. N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors
NZ241979A (en) * 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
JPH07506363A (ja) * 1992-04-30 1995-07-13 スミスクライン・ビーチャム・コーポレイション 17αおよび17β−置換のエストラ−1,3,5(10)−トリエン−3−カルボン酸
WO1993023040A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. 17-ethers and thioethers of 4-aza-steroids
EP0649306B1 (en) * 1992-05-20 2001-01-10 Merck & Co. Inc. Ester derivatives of 4-aza-steroids
US5620986A (en) * 1992-05-20 1997-04-15 Merck & Co., Inc. 17 urea, thiourea, thiocarbamyl and carbamyl4-azasteroid 5-reductase inhibitors useful in the prevention and treatment of hyperandrogenic disorders
WO1993023038A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. 17-AMINO SUBSTITUTED 4-AZASTEROID 5α-REDUCTASE INHIBITORS
US5237064A (en) * 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
WO1993023419A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. NEW 7β-SUBSTITUTED-4-AZA-5α-CHOLESTAN-ONES AS 5α-REDUCTASE INHIBITORS
US5324734A (en) * 1992-09-15 1994-06-28 Merck & Co., Inc. Oxidization metabolites of 5-α-23-methyl-4-aza-21-nor-chol-1-ene-3, 20-dione
US5278159A (en) * 1992-10-06 1994-01-11 Merck & Co., Inc. Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
US5683995A (en) * 1992-11-18 1997-11-04 Smithkline Beecham Corporation 17 substituted acyl-3-carboxy 3,5-diene steroidals as α-reductase inhibitors
US5641765A (en) * 1992-11-18 1997-06-24 Smithkline Beecham Corporation 17-αand 17-βsubstituted acyl-3-carboxy-3,5-dienes and use in inhibiting 5-α-reductase
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids
WO1994021614A1 (en) * 1993-03-24 1994-09-29 Merck & Co., Inc. SUBSTITUTED 3-PHENANTHRIDINONE DERIVATIVES AS 5α-REDUCTASE INHIBITORS
ATE158301T1 (de) * 1993-06-28 1997-10-15 Merck & Co Inc 4-aza-pregnan-5-alpha-reductase isozym 1 inhibitoren
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5430157A (en) * 1993-12-13 1995-07-04 Eli Lilly And Company Reduced phenanthrenes
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
GB201102913D0 (en) 2011-02-18 2011-04-06 Univ Birmingham Novel therapeutic

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1107664B (de) * 1959-11-05 1961-05-31 Schering Ag Verfahren zur Herstellung neuer in 3-Stellung substituierter OEstratriene
US3622670A (en) * 1969-08-22 1971-11-23 American Home Prod Method of inducing ovulation
US4185101A (en) * 1977-08-11 1980-01-22 Schering Corporation 1,3,5(10),6,8-19-Nor-pregnapentaenes, their use as anti-psoriatic agents, and pharmaceutical formulations useful therefor
US4191759A (en) * 1978-04-13 1980-03-04 Merck & Co., Inc. N-substituted-17β-carbamoylandrost-4-en-3-one 5α reductase inhibitors
US4340602A (en) * 1978-10-18 1982-07-20 Wayne State University Compositions inhibiting estrogen sulfotransferase activity
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors

Also Published As

Publication number Publication date
ES2065378T3 (es) 1995-02-16
HK1006461A1 (en) 1999-02-26
PT90656B (pt) 1994-10-31
EP0343954A3 (en) 1990-05-16
JP2675418B2 (ja) 1997-11-12
AU627466B2 (en) 1992-08-27
GR3015135T3 (en) 1995-05-31
AU3748789A (en) 1989-12-12
NO894065D0 (no) 1989-10-11
NO174964C (no) 1994-08-10
DK169787B1 (da) 1995-02-27
IE891732L (en) 1989-11-25
ATE114665T1 (de) 1994-12-15
EP0343954A2 (en) 1989-11-29
DK168295B1 (da) 1994-03-07
IL91968A (en) 1994-10-21
DK279790A (da) 1990-11-23
DK130393D0 (da) 1993-11-19
JPH03504498A (ja) 1991-10-03
CA1331457C (en) 1994-08-16
IE68858B1 (en) 1996-07-24
DK279790D0 (da) 1990-11-23
DE68919537T2 (de) 1995-05-11
WO1989011282A1 (en) 1989-11-30
PT90656A (pt) 1989-11-30
EP0343954B1 (en) 1994-11-30
NO174964B (no) 1994-05-02
DK130393A (da) 1993-11-19
DE68919537D1 (de) 1995-01-12
ZA893971B (en) 1990-05-30

Similar Documents

Publication Publication Date Title
DK279790D0 (da) Aromatiske steroid-5-alfa-reduktaseinhibitorer
ATE118505T1 (de) Phosphinsäure-derivate von aromatischen steroiden als 5-alpha reduktase-inhibitoren.
ATE114666T1 (de) Phosphonsäure-derivate von aromatischen steroiden als 5-alpha-reduktase-inhibitoren.
DE68920128D1 (de) Sulfonsäure-substituierte aromatische Steroide als 5-Alpha-Reduktase-Inhibitoren.
DE68914793D1 (de) Chinazolinon-Derivate.
NO945084L (no) Substituerte heterocykliske karboksylsyreamider, deres fremstilling og anvendelse som legemiddel
SE8804036D0 (sv) New use of 11,28-dioxa-4-azatricyclo(22.3.1.0?724,9 )octacos-18-ene derivatives and pharmaceutical compositions containing them
ATE150964T1 (de) Restenosehemmer nach perkutaner koronarer arterioplastie
DE69215694D1 (de) Benzamid-derivate
DE68909107D1 (de) 4-Amino-3-acylchinolin-Derivate und ihre Verwendung als Inhibitoren der Magensekretion.
ES538847A0 (es) Un derivado de fenilserina
AU4730889A (en) Novel carboximidamide derivatives
ATE95697T1 (de) Uricosuretische zusammensetzung.
ES2056211T3 (es) Derivados de acilsulfonamida de acidos alfa-carbocicliltoluicos usados como antagonistas de leucotrienos.